This article is more than 5 years old. Information may no longer be current.
Deferred HCV therapy in MSM with HIV/HCV increases risk for mortality
Click Here to Manage Email Alerts
Researchers recently reported that men who have sex with men coinfected with HIV and hepatitis C virus who deferred HCV treatment until evidence of advanced liver fibrosis appeared to have an increased risk for mortality and morbidity.
“Our findings support current recommendations to start HCV treatment irrespective of fibrosis stage in those with risk factors for accelerated fibrosis progression, including HIV-coinfected MSM, and in persons at elevated risk of HCV transmission,” Andri Rauch, MD, from the department of infectious diseases at Bern University Hospital, Switzerland, and colleagues wrote.
The researchers developed an individual-based model of liver disease progression in MSM with HIV/HCV coinfection enrolled in the Swiss HIV Cohort Study. They estimated liver-related morbidity, mortality and median time of HCV replication when patients were treated in liver fibrosis stages F0, F1, F2, F3 or F4, based on the METAVIR scale.
Overall, 2% of patients died of liver-related complications when treatment was initiated in F0 or F1; 3% died if treatment was deferred until stage F2; 7% died when deferred until stage F3; and 22% died when treatment was deferred to stage F4.
The median time patients had with HCV replication increased from 5 years if treatment was initiated in stage F2 to about 15 years if treatment was deferred until stage F4.
“Our model predicts that the time individuals spend with replicating HCV can be greatly shortened by early treatment,” the researchers wrote. “This may decrease further HCV transmissions in those with high-risk behavior.” – by Melinda Stevens
- Reference:
- Zahnd C, et al. J Hepatol. 2016;doi:10.1016/j.jhep.2016.02.030.
Disclosure: Rauch reports receiving grants and/or honoraria for advising, unrestricted grants and travel grants from AbbVie; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Merck; and ViiV Healthcare. Please see the full study for a list of all other authors’ relevant financial disclosures.